Amicus Therapeutics provides solutions to Lysosomal disorders

Amicus Therapeutics is one of the leading pharmaceutical company in the treatment of Lysosomal storage diseases. It is a biopharmaceutical company which bases its operations in Cranbury, New Jersey although they have expanded and opened another research center in San Diego. Major world investors founded the company like of New Enterprises Associates, Radius Ventures, and Canaan Partners.

 

Amicus Therapeutics develops and launches drugs that target treatment of a rare disease, Lysosomal storage disorders. Amicus Therapeutics products are derived from the technology in Chaperone Advanced Therapy (CHART). The company has also resonated in the development of Enzyme Replacement Therapies ( ERTs). Amicus Therapeutics uses pharmacological chaperones which associate themselves to the patients` defective enzymes for it to restore their work in the human body. Other ordinary types of treatment focus on replacing the affected enzymes. Currently, Amicus Therapeutics Company has the vast portfolio of pharmacological chaperones compared to other competing biopharmaceutical firms.

 

They have come up with a drug pipeline including Migalastat which was developed in 2014. Migalastat is an improved chaperone which targets the treatment of Fabry Disease. The drug stabilizes the mutant, alpha-galactosidase. Before the development of Migalastat, they had researched and launched the candidate drug AT2220 an enzyme replacement therapy which targets the treatment of Pombe disease.

 

Amicus Therapeutics Company has earned reputation over years of its service delivery and has formed the firm bond with its clients. They received an award of $ 210,300 from Alzheimer`s Drug Discovery Foundation. It has acquired a lot of profit and wealth through its pharmaceutical venture.

 

Amicus Therapeutics Pharmaceutical Company is now leading in business and science industry. As a firm, it is scientifically driven in the delivery of healthcare services and valuable benefits to the Amicus Therapeutics` patients in all corners of the world. The company has the best-advanced technology for the treatment of the lysosomal storage disorder which is operated by a team of experienced, qualified and certified doctors and practitioners of health care services (GoogleFinance). The company puts the professionals at the forefront of researching and developing therapies to curb and treat the cases of rare and orphan diseases and even neurodegenerative diseases.

More about Amicus Therapeutics on Crunchbase | Facebook